Triptans like sumatriptan are selective 5-HT1B/1D receptor agonists. They cause cranial vasoconstriction and inhibit trigeminal nerve release of neuropeptides, effectively aborting migraine attacks. They do not act significantly on 5HT-1A, 5HT-1F, or 5HT-3 receptors.